BioSpace News Archive

AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens.

Eckert & Ziegler and a subsidiary of POINT Biopharma Global Inc. have signed an agreement on the supply of Actinium-225.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”) today announced it has dosed the first patient in an Expanded Access Program (EAP) for patients with ALS who do not qualify for existing clinical trials and that the EAP will be fully funded by a grant from the NINDS under the ACT for ALS.

Novavax, Inc. (Nasdaq: NVAX) will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.

Endotronix, Inc. today announced its PROACTIVE-HF pivotal study successfully completed enrollment. Designed to evaluate the safety and efficacy of the Cordella™ Pulmonary Artery (PA) Sensor, the data will support the pre-market approval (PMA) application for market access in the U.S.

Foresight Diagnostics, a leader in molecular cancer diagnostics, announced the presentation of a study in collaboration with a leading cancer center at the upcoming annual meeting of the American Association for Cancer Research (AACR).

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Tuesday, May 2, 2023 at 8:30 a.m. ET.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data for both of its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association for Cancer Research (AACR), held in Orlando, FL, from 14 – 19 April 2023.

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”) today announced publication of human genomic and in vivo preclinical data linking iron regulation to polycythemia vera (PV) in the latest issue of Blood, the medical journal of the American Society of Hematology (ASH).

Nutriband Inc. with Kindeva Drug Delivery have selected the target AVERSA™ formulation to take forward into commercial scale manufacturing process development for the Company’s patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.